Microfluidics Device Captures and Isolates Slow Growing Gut Bacteria
|
By LabMedica International staff writers Posted on 15 Jul 2014 |

Image: Glass SlipChip for growing microbes, shown next to a US quarter dollar coin (left); fluorescent in situ hybridization image of the target organism (right, top); transmission electron microscopy image of a single cell of the target organism (right, bottom) (Photo courtesy of the California Institute of Technology).
Microbiologists have used a novel "lab-on-a-chip" approach to isolate and cultivate fastidious, slow growing bacteria from the human digestive tract.
The majority of microbes that comprises the human gut biome have not been cultured, due in part to the difficulties of both identifying proper growth conditions and characterizing and isolating each species.
Investigators at the California Institute of Technology (Pasadena, USA) developed a microfluidics-based, genetically targeted approach to overcome these problems. Their "SlipChip" device was constructed from two glass slides, each the size of a credit card, that were etched with tiny grooves that became channels when the grooved surfaces were stacked atop one another. When a sample, such as a mixed assortment of bacterial species from a colonoscopy biopsy, was applied to the device, the interconnected channels of the top chip turned the channels into individual wells, with each well ideally holding a single microbe. Once sequestered in an isolated well, each individual bacterium was able to divide and grow without having to compete for resources with other types of faster-growing microbes.
The beauty of the system was that each well could be divided into two compartments. One compartment was used for DNA sequencing and mapping studies while the other maintained a living example of the microbe for further culture and study.
The investigators validated this approach by cultivating a bacterium from a human cecal biopsy. Genetic mapping of the organism showed that it was a representative of a previously unidentified genus of the Ruminococcaceae family and that its genetic signature was listed among the high-priority group of the [US] National Institutes of Health's Human Microbiome Project’s "Most Wanted" list.
"Although a genomic sequence of the new organism is a useful tool, further studies are needed to learn how this species of microbe is involved in human health," said senior author Dr. Rustem Ismagilov, professor of chemistry and chemical engineering at the California Institute of Technology.
The study was published in the June 25, 2014, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
California Institute of Technology
The majority of microbes that comprises the human gut biome have not been cultured, due in part to the difficulties of both identifying proper growth conditions and characterizing and isolating each species.
Investigators at the California Institute of Technology (Pasadena, USA) developed a microfluidics-based, genetically targeted approach to overcome these problems. Their "SlipChip" device was constructed from two glass slides, each the size of a credit card, that were etched with tiny grooves that became channels when the grooved surfaces were stacked atop one another. When a sample, such as a mixed assortment of bacterial species from a colonoscopy biopsy, was applied to the device, the interconnected channels of the top chip turned the channels into individual wells, with each well ideally holding a single microbe. Once sequestered in an isolated well, each individual bacterium was able to divide and grow without having to compete for resources with other types of faster-growing microbes.
The beauty of the system was that each well could be divided into two compartments. One compartment was used for DNA sequencing and mapping studies while the other maintained a living example of the microbe for further culture and study.
The investigators validated this approach by cultivating a bacterium from a human cecal biopsy. Genetic mapping of the organism showed that it was a representative of a previously unidentified genus of the Ruminococcaceae family and that its genetic signature was listed among the high-priority group of the [US] National Institutes of Health's Human Microbiome Project’s "Most Wanted" list.
"Although a genomic sequence of the new organism is a useful tool, further studies are needed to learn how this species of microbe is involved in human health," said senior author Dr. Rustem Ismagilov, professor of chemistry and chemical engineering at the California Institute of Technology.
The study was published in the June 25, 2014, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
California Institute of Technology
Latest Microbiology News
- Syndromic Panel Enables Rapid Identification of Bloodstream Infections
- RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
- Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
- New Bacterial Target Identified for Early Detection of Noma
- Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
- Rapid Urine Test Speeds Antibiotic Selection for UTIs
- WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
- Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
- Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
- WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
- New Imaging Approach Could Help Predict Dangerous Gut Infection
- Rapid Sequencing Could Transform Tuberculosis Care
- Blood-Based Viral Signature Identified in Crohn’s Disease
- Hidden Gut Viruses Linked to Colorectal Cancer Risk
- Three-Test Panel Launched for Detection of Liver Fluke Infections
- Rapid Test Promises Faster Answers for Drug-Resistant Infections
Channels
Clinical Chemistry
view channel
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more
Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy
Routine blood tests that measure low-density lipoprotein (LDL), commonly known as “bad” cholesterol, are widely used to guide lipid-lowering therapy, but they do not always provide a complete picture of... Read more
AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read moreNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read moreMolecular Diagnostics
view channel
Blood-Based Epigenetic Signals Enable Osteosarcoma Disease Monitoring
Osteosarcoma is a rare but aggressive pediatric bone cancer where recurrence and metastasis remain difficult to detect early. Imaging-based surveillance can miss small lesions and exposes children to repeated... Read more
Host–Virus Genetic Interactions Drive Nasopharyngeal Cancer Risk
Epstein–Barr virus (EBV) infects more than 95% of adults worldwide, yet only a small fraction develops EBV‑associated cancers such as nasopharyngeal carcinoma. Explaining this divergence requires understanding... Read moreHematology
view channel
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read more
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read moreImmunology
view channel
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read morePathology
view channel
Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer
Colorectal cancer is common and often lethal, and therapeutic decision-making is complicated by heterogeneous tumor microenvironments. Immunotherapy benefits only a small subset of patients, around 5%,... Read more
Collaboration Applies AI Pathology to Predict Response to Antibody-Drug Conjugates
Antibody-drug conjugates (ADC) are reshaping oncology, yet scalable biomarkers that reliably predict which patients will benefit remain limited as treatment regimens and combinations grow more complex.... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring
Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more







